Last reviewed · How we verify
Intratumoral injections of L19IL2
Intratumoral injections of L19IL2 is a Immunocytokine Small molecule drug developed by Philogen S.p.A.. It is currently in Phase 2 development for Treatment of various cancers.
L19IL2 is an immunocytokine that targets the EDB domain of fibronectin, which is overexpressed in tumor vasculature, and delivers IL-2 to the tumor microenvironment to stimulate an anti-tumor immune response.
L19IL2 is an immunocytokine that targets the EDB domain of fibronectin, which is overexpressed in tumor vasculature, and delivers IL-2 to the tumor microenvironment to stimulate an anti-tumor immune response. Used for Treatment of various cancers.
At a glance
| Generic name | Intratumoral injections of L19IL2 |
|---|---|
| Sponsor | Philogen S.p.A. |
| Drug class | Immunocytokine |
| Target | EDB domain of fibronectin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By targeting the EDB domain of fibronectin, L19IL2 selectively binds to tumor-associated blood vessels, allowing IL-2 to be delivered directly to the tumor site. This localized delivery of IL-2 stimulates the expansion and activation of tumor-specific T cells, leading to an anti-tumor immune response.
Approved indications
- Treatment of various cancers
Common side effects
- Injection site reactions
- Fatigue
- Nausea
Key clinical trials
- L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) (PHASE2)
- L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma (PHASE2)
- L19IL2/TNF in Patients With Basal Cell Carcinoma (PHASE2)
- Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients (PHASE3)
- Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients (PHASE2)
- Neoadjuvant L19IL2/L19TNF- Pivotal Study (PHASE3)
- Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients (PHASE2)
- Intratumoral Administration of L19IL2/L19TNF (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intratumoral injections of L19IL2 CI brief — competitive landscape report
- Intratumoral injections of L19IL2 updates RSS · CI watch RSS
- Philogen S.p.A. portfolio CI
Frequently asked questions about Intratumoral injections of L19IL2
What is Intratumoral injections of L19IL2?
How does Intratumoral injections of L19IL2 work?
What is Intratumoral injections of L19IL2 used for?
Who makes Intratumoral injections of L19IL2?
What drug class is Intratumoral injections of L19IL2 in?
What development phase is Intratumoral injections of L19IL2 in?
What are the side effects of Intratumoral injections of L19IL2?
What does Intratumoral injections of L19IL2 target?
Related
- Drug class: All Immunocytokine drugs
- Target: All drugs targeting EDB domain of fibronectin
- Manufacturer: Philogen S.p.A. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Treatment of various cancers
- Compare: Intratumoral injections of L19IL2 vs similar drugs
- Pricing: Intratumoral injections of L19IL2 cost, discount & access